CN1872831A - Method for preparing key intermediate of medication for anti AIDS - Google Patents
Method for preparing key intermediate of medication for anti AIDS Download PDFInfo
- Publication number
- CN1872831A CN1872831A CN 200510049933 CN200510049933A CN1872831A CN 1872831 A CN1872831 A CN 1872831A CN 200510049933 CN200510049933 CN 200510049933 CN 200510049933 A CN200510049933 A CN 200510049933A CN 1872831 A CN1872831 A CN 1872831A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- ethyl
- methyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
This invention discloses a method for manufacturing the intermediate of an anti-AIDS drug. The method uses phenyl aldehyde as the raw material, and subjects it to condensation, reduction, Grignard reaction and hydrolysis to obtain (R)-3-hydroxyl-3-(20phenylethyl)-hexanoic acid. The yield is 50-60%.
Description
Technical field
The invention belongs to the chemical pharmaceutical technical field, relate to the preparation method of key intermediate (R)-3-hydroxyl-3-(2-phenylethyl)-caproic acid formula (2) compound of a kind of inverase TIPRANAVIR.
Background technology
TIPRANAVIR, formula (1) compound is a kind of HIV-1 proteinase inhibitor.
(R)-and 3-hydroxyl-3-(2-phenylethyl)-caproic acid, formula (2) compound is the key intermediate of TIPRANAVIR.
The synthetic method of disclosed (R)-3-hydroxyl-3-(2-phenylethyl)-caproic acid mainly contains following several in the prior art:
At J.Org.Chem.1998 63, having described a kind of among the 7348-7356 is starting raw material with 3-benzene hexanone, makes 3-hydroxyl-3-(2-the phenylethyl)-caproic acid of DL then with the lithium salts reaction of ethyl acetate.Obtain (R)-3-hydroxyl-3-(2-phenylethyl)-caproic acid by splitting with (-) norephedrine.According to present method, need dialkylamino lithium and ethyl acetate be made the lithium salts of ethyl acetate, processing condition harshness at low temperature-78 ℃; Simultaneously, at industrial use (-) norephedrine certain difficulty is arranged; Total recovery is about 27%, the production cost height.
Disclosing a kind of in US2004138496 is starting raw material with the phenyl aldehyde, and after the 2 pentanone condensation, shortening obtains the benzene hexanone again.Make 3-hydroxyl-3-(2-the phenylethyl)-caproic acid of DL through grignard reaction, split with Chiral Amine then, obtain target compound.This method operation feasible, but three wastes treatment capacity is bigger, and total recovery is on the low side to be about 35%.
Summary of the invention
The objective of the invention is provides a kind of method for preparing TIPRANAVIR key intermediate (R)-3-hydroxyl-3-(2-phenylethyl)-caproic acid efficiently in order to improve the overall yield of (R)-3-hydroxyl-3-(2-phenylethyl)-caproic acid.This law is bright to be to be starting raw material with phenyl aldehyde and methyl aceto acetate, and condensation makes benzene methene methyl aceto acetate formula (3) compound under the alkali effect.
Gained formula (3) compound need not purifying, and with 5～10 normal atmosphere, 5% palladium charcoal is that catalyst to catalyzing hydrogenating gets formula (4) compound.
Grignard reaction takes place in gained formula (4) compound and propyl group magnesium bromide under the effect of micro-chiral catalyst, obtain (R)-3-hydroxyl-3-(2-phenylethyl)-ethyl hexanoate formula (5) compound, hydrolysis obtains (R)-3-hydroxyl-3-(2-phenylethyl)-caproic acid formula (2) compound again.
This anti-AIDS drug key intermediate compound as following structural formula (2), its preparation method is following steps:
A, be benzene methene methyl aceto acetate formula (3) compound with phenyl aldehyde and methyl aceto acetate condensation;
B, the condenses benzene methene methyl aceto acetate formula (3) among the step a is reduced to phenylpropyl alcohol ethyl acetoacetic acid ethyl ester formula (4) compound;
C, with the reduzate phenylpropyl alcohol ethyl acetoacetic acid ethyl ester formula (4) among the step b under the effect of chiral reagent with N-PROPYLE BROMIDE generation grignard reaction, generate (R)-3-hydroxyl-3-(2-phenylethyl)-ethyl hexanoate formula (5) compound;
D, with product (R)-3-hydroxyl-3-(2-phenylethyl)-ethyl hexanoate formula (5) hydrolysis of gained among the step c, obtain formula (2) compound.
The chiral reagent of described step c is: racephedrine and derivative thereof comprise racephedrine or methyl ephedrine or etafedrine.
Described step b carries out in the solvent of ethyl acetate or isopropyl formate or t-butyl formate or tetrahydrofuran (THF) or toluene.
Described step c carries out in tetrahydrofuran (THF) or ether or methyl ethyl ether or t-butyl methyl ether or tertiary butyl ether solvent.
Total recovery of the present invention is 58.1%.With existent method ratio, yield height, quantity of three wastes is few, product chiral purity height.Be a kind of economy, efficient, have the technology that suitability for industrialized production is worth.
(R)-3-hydroxyl-3-(2-the phenylethyl)-caproic acid chiral purity of gained of the present invention is greater than 99.0%.Can be according to produce needing, to make content be more than 99% or industrial acceptable content is 50～99% ketone solution with product, the ketone of indication is ketones solvents such as acetone, methylethylketone, mibk.
Except as otherwise noted, the temperature of indication of the present invention is degree centigrade; The chiral reagent of indication is racephedrine and the derivative thereof as following structural formula:
Wherein R is the alkyl of C1-C7.
Solvent of the present invention refers to the solvent used always, as: benzene, toluene, dimethylbenzene, dioxane, N, dinethylformamide, N,N-dimethylacetamide, methylene dichloride, trichloromethane, tetracol phenixin, ethylene dichloride, methyl alcohol, ethanol, propyl alcohol, Virahol, butanols, Virahol, the trimethyl carbinol, ethyl acetate, isopropyl formate, t-butyl formate, tetrahydrofuran (THF), acetone, methylethylketone, mibk etc.
Embodiment
The following example is used to further specify the present invention, is not any restriction to scope of the present invention.
The fusing point of all compounds is all measured on the fusing point instrument, and chiral purity and assay are measured on the HP1100 high performance liquid chromatograph.
Implementation step 1: the preparation of benzene methene methyl aceto acetate formula (3) compound:
Drop into 15 gram phenyl aldehydes in the three-necked flask of 100ml, drop into 40 gram methyl aceto acetates again, the stirring heating reaction is warming up to 95 ℃, drips the NaOH solution of 20 grams 2.5%, is incubated 8 hours.Material is cooled to 30 ℃, standing demix.The organic layer concentrating under reduced pressure reclaims methyl aceto acetate.After decompression finishes, get formula (3) compound product 30.1 grams.HPLC detects, and content is greater than 95%.Yield is 95%.
Implementation step 2: the preparation of phenylpropyl alcohol ethyl acetoacetic acid ethyl ester formula (4) compound:
In the autoclave of 500ml, drop into formula (3) product, the 120 gram ethyl acetate, 2 that make in the 250 gram implementation steps 1 and restrain 5% palladium charcoal.Feed intake finish after, use nitrogen replacement.Stir, with feed liquid heat temperature raising to 65 ℃.Feed hydrogen, pressure keeps 1.0Mpa, is incubated 24 hours.Feed liquid is cooled to 45 ℃, and press filtration concentrates filtrate decompression, gets formula (4) compound crude product.Crude product is put in the reaction flask that has rectifier unit, reduced pressure, heat up, vacuum tightness 5mmHg, temperature concentrates down less than 130 ℃, collects boiling point at 110 to 120 ℃ of following products, gets formula (4) compound products 225 grams, and the HPLC detection level is 96.5%.
Implementation step 3:(R)-preparation of 3-hydroxyl-3-(2-phenylethyl)-ethyl hexanoate formula (5) compound
In three-necked flask, add tetrahydrofuran (THF) 30 grams, magnesium silk 4.5 grams, stir and be warming up to 40 ℃.In 4 hours, add the mixing solutions that contains the phenylpropyl alcohol ethyl acetoacetic acid ethyl ester, 22 gram N-PROPYLE BROMIDEs, 2 gram racephedrines, 4.5 gram zinc chloride and the 15 gram tetrahydrofuran (THF)s that obtain in the 20 gram implementation steps 2 then.After dropwising, be incubated 3 hours.Feed liquid is added drop-wise in the mixing solutions of 50 hydrochloric, deionized waters of gram and ammonium chloride (ratio is 3: 6: 1).NaOH solution with 10% is transferred pH value to 5.5.In 30 ℃ of stirrings 30 minutes, leave standstill layering.Organic layer is filtered, and filtrate decompression concentrates.Get formula (5) compound products 16 grams, the HPLC detection level is 94.2%.
Implementation step 4:(R)-preparation of 3-hydroxyl-3-(2-phenylethyl)-caproic acid formula (2) compound
In three-necked flask, add mibk 35 grams, (R)-3-hydroxyl-3-(2-phenylethyl)-ethyl hexanoate formula (5) compound 15 grams, stir, attemperation to 30 drips 10% sulfuric acid, 35 grams that configured in advance to 40 ℃, continue to stir insulation 1 hour, left standstill 30 minutes.Divide water-yielding stratum, in organic layer, add 15 gram deionized waters, stirred 30 minutes, leave standstill, divide water-yielding stratum.The organic layer concentrating under reduced pressure gets finished product formula (2) compound 20 grams, and the HPLC detection level is 60%, and chiral purity (ee value) is 99.2%.Total recovery is 52%.
Can product be made into the ketone solution of different content or utilize industrial enforceable way that product is purified according to producing needs.
Claims (4)
1, a kind of preparation method of anti-AIDS drug key intermediate compound of as following structural formula (2) is characterized in that following steps:
A, be benzene methene methyl aceto acetate formula (3) compound with phenyl aldehyde and methyl aceto acetate condensation;
B, the condenses benzene methene methyl aceto acetate formula (3) among the step a is reduced to phenylpropyl alcohol ethyl acetoacetic acid ethyl ester formula (4) compound;
C, with the reduzate phenylpropyl alcohol ethyl acetoacetic acid ethyl ester formula (4) among the step b under the effect of chiral reagent with N-PROPYLE BROMIDE generation grignard reaction, generate (R)-3-hydroxyl-3-(2-phenylethyl)-ethyl hexanoate formula (5) compound;
D, with product (R)-3-hydroxyl-3-(2-phenylethyl)-ethyl hexanoate formula (5) hydrolysis of gained among the step c, obtain formula (2) compound.
2, by the preparation method of claim 1, the chiral reagent of described step c is: racephedrine and derivative thereof comprise racephedrine or methyl ephedrine or etafedrine.
3, by the preparation method of claim 1 or 2, described step b carries out in the solvent of ethyl acetate or isopropyl formate or t-butyl formate or tetrahydrofuran (THF) or toluene.
4, by the preparation method of claim 1 or 2, described step c carries out in tetrahydrofuran (THF) or ether or methyl ethyl ether or t-butyl methyl ether or tertiary butyl ether solvent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100499330A CN100448836C (en) | 2005-06-03 | 2005-06-03 | Method for preparing key intermediate of medication for anti AIDS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100499330A CN100448836C (en) | 2005-06-03 | 2005-06-03 | Method for preparing key intermediate of medication for anti AIDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872831A true CN1872831A (en) | 2006-12-06 |
| CN100448836C CN100448836C (en) | 2009-01-07 |
Family
ID=37483453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100499330A Expired - Fee Related CN100448836C (en) | 2005-06-03 | 2005-06-03 | Method for preparing key intermediate of medication for anti AIDS |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100448836C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107663150A (en) * | 2016-07-27 | 2018-02-06 | 西南民族大学 | A kind of fast synthesis method of zingiberene phenolic compound |
| CN109748786A (en) * | 2018-12-30 | 2019-05-14 | 深圳瀜新生物科技有限公司 | A kind of synthetic method of the compound as neuroprotective agent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100569771B1 (en) * | 1997-09-11 | 2006-04-11 | 파마시아 앤드 업존 캄파니 엘엘씨 | Process to Produce 4-Hydroxy-2-Oxo-Pyrane Derivates Useful as Protease Inhibitors |
| JP2003137835A (en) * | 2001-10-30 | 2003-05-14 | Sumika Fine Chemicals Co Ltd | Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid |
| CA2475332A1 (en) * | 2002-02-07 | 2003-08-14 | Sumitomo Chemical Company, Limited | Process for producing (r)-3-hydroxy-3-(2-phenylethyl)hexanoic acid and its intermediate |
-
2005
- 2005-06-03 CN CNB2005100499330A patent/CN100448836C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107663150A (en) * | 2016-07-27 | 2018-02-06 | 西南民族大学 | A kind of fast synthesis method of zingiberene phenolic compound |
| CN109748786A (en) * | 2018-12-30 | 2019-05-14 | 深圳瀜新生物科技有限公司 | A kind of synthetic method of the compound as neuroprotective agent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100448836C (en) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872831A (en) | Method for preparing key intermediate of medication for anti AIDS | |
| CN105198707A (en) | 4-biphenyl methanol synthetic method | |
| CN1317268C (en) | 2,6-dimethylpyridine preparation method | |
| CN108947800B (en) | Synthesis method of (1S) -4, 5-dimethoxy-1- (carbonylaminomethyl) benzocyclobutane | |
| CN107162920B (en) | A kind of preparation method of R-1- amino -2- propyl alcohol | |
| CN116143658A (en) | Method for simultaneously preparing tripropylacetonitrile, tripropylamide and tripropylacetic acid | |
| CN102060734B (en) | Method for preparing N-(4-ethyoxylcarbonylphenyl)-N'-methyl-N'-phenyl carbonamidine | |
| CN112645813B (en) | Preparation method of (R) -3-cyclohexene carboxylic acid | |
| CN1824646A (en) | Aryl or aryl amine substuted quinone kind compound and its preparation method | |
| CN104262169B (en) | The preparation of R-2-tetrahydro naphthylamine | |
| CN1626504A (en) | Method for preparing Tolterodine and tartrate | |
| WO2010046808A2 (en) | A process for the preparation of venlafaxine hydrochloride | |
| CN1247737C (en) | Liquid antioxidant and its preparing method | |
| CN1239460C (en) | Synthesis of trans-4-alkyl cyclohexyl formic acid | |
| CN1266116C (en) | Venlafaxine and its salt preparing method | |
| CN101050218A (en) | Method for synthesizing MU - oxygen substitutional binuclear metalloporphyrin | |
| CN101987825A (en) | Method for preparing 2-amino-3-methyl-4-methoxy acetophenone | |
| CN1211380C (en) | Method of preparing 2,4,6-triisopropanyl-1,3,5-trioxy oxane | |
| CN102020600B (en) | Synthetic method of indole-2-carboxylic acid | |
| CN110467539B (en) | Resolution method of 2,6-dimethyl tyrosine ester and application thereof | |
| CN1915940A (en) | Method for synthesizing methyl azulenoids | |
| CN1958573A (en) | Method for preparing compound of 1, 2 (dodecyl) 4 hydroxide methylene - 3, 5 pyrazole | |
| CN112811991A (en) | Synthesis method of p-methoxystyrene | |
| CN1369473A (en) | Method for preparing cis-6-hexadecenoic acid | |
| CN102617279B (en) | Method for preparing alcohol compounds by amine compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG PROVINCE JIUZHOU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHEJIANG ZHONGBEI CHEMICAL INDUSTRY CO., LTD. Effective date: 20091211 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20091211 Address after: Jiaojiang District of Taizhou City, Zhejiang Province Road outside No. 99 Patentee after: ZHEJIANG JIUZHOU PHARMACEUTICAL Co.,Ltd. Address before: No. 2, Haicheng Road, rock head Industrial Development Zone, Jiaojiang, Zhejiang, Taizhou Patentee before: Zhejiang Zhongbei Chemical Co.,Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Zhejiang Zhongbei Chemical Co.,Ltd. Assignor: ZHEJIANG JIUZHOU PHARMACEUTICAL Co.,Ltd. Contract record no.: 2010330001900 Denomination of invention: Method for preparing key intermediate of medication for anti AIDS Granted publication date: 20090107 License type: Exclusive License Open date: 20061206 Record date: 20100920 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090107 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |